
    
      This study plans to enroll 10 patients to assess the safety and efficacy of spCART-269.
      Subjects who meet the eligibility criteria will receive a single dose of spCART-269
      injection. The study will include the following sequential phases: Screening, Pre-treatment
      (Cell product preparation; Lymphodepleting Chemotherapy), Treatment and follow-up.
    
  